Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Colorectal Carcinomatosis (BEV-IP)
NCT03161041Phase 2Withdrawn
- Sponsor
- Hospices Civils de Lyon
- Start
- Sep 2018
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of bevacizumab in colorectal carcinoma (CRC) and appendiceal adenocarcinoma, sponsored by Hospices Civils de Lyon. Planned start Sep 2018; status: withdrawn.
02
Drugs
bevacizumab
03
Conditions
colorectal carcinoma (CRC)appendiceal adenocarcinoma
Beyond the preview
Go deeper on NCT03161041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03161041.